

SUPPLEMENTAL MATERIAL

A clinically relevant variant of the human hydrogen sulfide-synthesizing enzyme cystathionine β -synthase: increased CO reactivity as a novel molecular mechanism of pathogenicity?

João B. Vicente^{1,*}, Henrique G. Colaço², Francesca Malagrino^{3,4}, Paulo E. Santo^{1,5}, André Gutierrez¹, Tiago M. Bandejas^{1,5}, Paula Leandro⁶, José A. Brito¹, and Alessandro Giuffrè^{3,*}

1 - Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal

2 - Instituto Gulbenkian da Ciência, Oeiras, Portugal

3 - CNR Institute of Molecular Biology and Pathology, Rome, Italy

4 - Department of Biochemical Sciences, Sapienza University of Rome, Italy.

5 - Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal

6 - Research Institute for Medicines and Department of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon, Portugal

Supplementary Figure 1. SDS-PAGE analysis of CBS preparations. Analysis of CBS samples employed in this study, corresponding to full-length CBS WT and p.P49L purified in the absence ('untreated') or presence ('treated') of PLP (20 μ M). Truncated WT and p.P49L CBS lacking the C-terminal AdoMet-binding domain were analyzed for comparison with the full-length protein. Denatured protein samples were loaded onto a pre-cast NuPAGETM 10% Bis-Tris gel (Invitrogen) and ran at 200 V. Protein bands were stained with InstantBlueTM (Expedeon) according to the manufacturer's instructions. Protein marker: NZYColour Protein Marker II (Nzytech).

